دورية أكاديمية
Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis.
| العنوان: | Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis. |
|---|---|
| المؤلفون: | Viegas JSR; School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Av. do Café s/n, Ribeirao Preto, SP, 14040-903, Brazil., Praça FG; School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Av. do Café s/n, Ribeirao Preto, SP, 14040-903, Brazil., Caron AL; School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Av. do Café s/n, Ribeirao Preto, SP, 14040-903, Brazil., Suzuki I; School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Av. do Café s/n, Ribeirao Preto, SP, 14040-903, Brazil., Silvestrini AVP; School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Av. do Café s/n, Ribeirao Preto, SP, 14040-903, Brazil., Medina WSG; Centro Universitário Padre Albino, Catanduva, SP, Brazil., Del Ciampo JO; School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Av. do Café s/n, Ribeirao Preto, SP, 14040-903, Brazil., Kravicz M; School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Av. do Café s/n, Ribeirao Preto, SP, 14040-903, Brazil., Bentley MVLB; School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Av. do Café s/n, Ribeirao Preto, SP, 14040-903, Brazil. vbentley@usp.br. |
| المصدر: | Drug delivery and translational research [Drug Deliv Transl Res] 2020 Jun; Vol. 10 (3), pp. 646-660. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: United States NLM ID: 101540061 Publication Model: Print Cited Medium: Internet ISSN: 2190-3948 (Electronic) Linking ISSN: 2190393X NLM ISO Abbreviation: Drug Deliv Transl Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York : Springer |
| مواضيع طبية MeSH: | Imiquimod/*adverse effects , Psoriasis/*drug therapy , RNA, Small Interfering/*administration & dosage , Tacrolimus/*administration & dosage , Tumor Necrosis Factor-alpha/*genetics, Administration, Cutaneous ; Animals ; Delayed-Action Preparations ; Disease Models, Animal ; Down-Regulation ; Drug Synergism ; Female ; Liposomes ; Male ; Mice ; Mice, Inbred BALB C ; NIH 3T3 Cells ; Nanoparticles ; Particle Size ; Psoriasis/chemically induced ; Psoriasis/genetics ; RNA, Small Interfering/pharmacology ; Tacrolimus/pharmacology ; Tumor Necrosis Factor-alpha/antagonists & inhibitors |
| مستخلص: | Since psoriasis is an immuno-mediated skin disease, long-term therapies are necessary for its treatment. In clinical investigations, tacrolimus (TAC), a macrolide immunosuppressive inhibitor of calcineurin, arises as an alternative for the treatment of psoriasis, acting in some cytokines involved in the pathogenesis of the disease. Here, we aim to study the psoriasis treatment with TAC and siRNA for one of most cytokines expressed in psoriasis, the TNF-α. A multifunctional nanostructure lipid carrier (NLC) was developed to co-delivery TAC and siRNA. Results showed that the particle size and zeta potential were around 230 nm and + 10 mV, respectively. The release study demonstrated a controlled release of TAC, and the permeation and retention profile in the skin tissue show to be promising for topical application. The cell viability and uptake in murine fibroblast presented low toxicity associated to uptake of NLC in 4 h, and finally, the in vivo animal model demonstrates the efficiency of the NLC multifunctional, exhibiting a reduction of the cytokine TNF-α expression about 7-fold and presenting a synergic effect between the TAC and TNF-α siRNA. The developed system was successfully to treat in vivo psoriatic animal model induced by imiquimod and the synergic combination was reported here for the first time. Graphical abstract. |
| فهرسة مساهمة: | Keywords: Gene therapy; Nanoparticle; Psoriasis; Tacrolimus; Topical application |
| المشرفين على المادة: | 0 (Delayed-Action Preparations) 0 (Lipid Nanoparticles) 0 (Liposomes) 0 (RNA, Small Interfering) 0 (Tnf protein, mouse) 0 (Tumor Necrosis Factor-alpha) P1QW714R7M (Imiquimod) WM0HAQ4WNM (Tacrolimus) |
| تواريخ الأحداث: | Date Created: 20200216 Date Completed: 20210702 Latest Revision: 20210702 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1007/s13346-020-00723-6 |
| PMID: | 32060883 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2190-3948 |
|---|---|
| DOI: | 10.1007/s13346-020-00723-6 |